Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLS III: Pirfenidone + MMF in SSc-ILD
NCT03221257Phase 2Completed
- Start
- Nov 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in interstitial lung disease (ILD) comparing Placebo + MMF with Pirfenidone + MMF (2 arms). Primary endpoint: Percent Predicted Forced Vital Capacity at 18 months. Started Nov 2017; status: completed.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT03221257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221257.